irpages2.eqs.com/websites/a...
Annovis AnnovisBio gets the nod from US_FDA for their Phase 3 clinical study of Buntanetap (Posiphen) in individuals recently diagnosed with #Parkinsons to proceed; 6 months; double-blind, placebo-controlled; 2 doses; N=450; 1# endpoint=UPDRS II+III OFF
"Buntanetap 10 mg, 20 mg, or placebo capsules, taken orally once a day for 6 months"
"in 100 sites in the US and EU"
"start recruiting for the US clinical trial soon, expected later this summer"
With 100 sites, it shouldn't take them too long to get 450 PwPs.
Golly - I do like news like this. Keep 'em coming
Hoping 3’s the charm!!!
I wish they would list the locations when they list the clinical trialclinicaltrials.gov/ct2/show...
They will list them when they start recruitment.
Is this symptomatic treatment or disease modifying
THANK YOU for posting this! Very encouraging stage 3 trial about to begin...
PNT article: FDA Gives Green Light to Phase 3 Trial of Buntanetap.parkinsonsnewstoday.com/new...
Annovis Bio announced today the completion of patient enrollment for its phase III Parkinson’s Disease trial in a record nine months
Annovis Bio's Phase 3 trial of Buntanetap/Posiphen: Trial record has been updated (contacts and locations)
Anxious to hear any updates from Annovis Bio Butanetap phase 3 trial cohorts
Neuraly Announces Topline Results from Phase 2 Trial of NLY01 in Parkinson's DiseaseStarting phase 2 trial : Terazosin for Parkinson's Disease (TZ-PD)
